- Home
- LPTX vs GNLN Comparison
LPTX vs GNLN Comparison
Compare LPTX & GNLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTX
- GNLN
- Stock Information
- Founded
- LPTX 2011
- GNLN 2005
- Country
- LPTX United States
- GNLN United States
- Employees
- LPTX N/A
- GNLN N/A
- Industry
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- GNLN Durable Goods
- Sector
- LPTX Health Care
- GNLN Consumer Discretionary
- Exchange
- LPTX Nasdaq
- GNLN Nasdaq
- Market Cap
- LPTX 11.1M
- GNLN 12.9M
- IPO Year
- LPTX N/A
- GNLN 2019
- Fundamental
- Price
- LPTX $0.31
- GNLN $3.56
- Analyst Decision
- LPTX Hold
- GNLN
- Analyst Count
- LPTX 1
- GNLN 0
- Target Price
- LPTX N/A
- GNLN N/A
- AVG Volume (30 Days)
- LPTX 710.1K
- GNLN 88.9K
- Earning Date
- LPTX 11-12-2025
- GNLN 11-14-2025
- Dividend Yield
- LPTX N/A
- GNLN N/A
- EPS Growth
- LPTX N/A
- GNLN N/A
- EPS
- LPTX N/A
- GNLN N/A
- Revenue
- LPTX N/A
- GNLN $7,954,000.00
- Revenue This Year
- LPTX N/A
- GNLN $1,541.21
- Revenue Next Year
- LPTX N/A
- GNLN N/A
- P/E Ratio
- LPTX N/A
- GNLN N/A
- Revenue Growth
- LPTX N/A
- GNLN N/A
- 52 Week Low
- LPTX $0.22
- GNLN $2.84
- 52 Week High
- LPTX $4.79
- GNLN $5,130.00
- Technical
- Relative Strength Index (RSI)
- LPTX 53.90
- GNLN 49.22
- Support Level
- LPTX $0.28
- GNLN $3.35
- Resistance Level
- LPTX $0.32
- GNLN $3.74
- Average True Range (ATR)
- LPTX 0.02
- GNLN 0.23
- MACD
- LPTX 0.00
- GNLN 0.09
- Stochastic Oscillator
- LPTX 73.33
- GNLN 58.67
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.
About GNLN Greenlane Holdings Inc.
Greenlane Holdings Inc is a platform for the development and distribution of premium cannabis accessories, vape devices, and lifestyle products. It provides a wide array of consumer ancillary products and industrial ancillary products to thousands of cannabis producers, processors, brands, and retailers (Cannabis Operators). In addition, it serves specialty retailers, smoke shops, head shops, convenience stores, and consumers directly through its proprietary web stores and large online marketplaces such as Amazon. Its geographical segment includes the United States, Canada, and Europe. It derives a majority of revenue from the United States.